Search results for " Antibodies"

showing 10 items of 383 documents

Overview of the second international workshop to define swine cluster of differentiation (CD) antigens

1998

The aim of the Second International Swine Cluster of Differentiation (CD) Workshop, supported by the Veterinary Immunology Committee (VIC) of the International Union of Immunological Societies (IUIS), was to standardize the assignment of monoclonal antibodies (mAb) reactive with porcine leukocyte differentiation antigens and to define new antibody clusters. At the summary meeting of the workshop in July, 1995, revisions in the existing nomenclature for the Swine CD were approved, so that the rules are now in accord with those for human and ruminant CD. Swine CD numbers will now be given to clusters of mAb to swine orthologues of human CD molecules when homology is proven by (1) suitable tis…

medicine.drug_classSwineCD3ImmunologyCluster of differentiation CDSwine; Cluster of differentiation (CD); Antigens; Monoclonal antibodies (mAb)Monoclonal antibodyEpitopeImmune systemAntigenMonoclonal antibodies (mAb)medicineAntigensInstituut voor Dierhouderij en DiergezondheidCluster of differentiation (CD)CD antigenGeneral VeterinaryCluster of differentiationbiologyID-LelystadVirologyID LelystadID-Lelystad Instituut voor Dierhouderij en DiergezondheidImmunologyID Lelystad Institute for Animal Science and Healthbiology.proteinAntibodyInstitute for Animal Science and Health
researchProduct

Screening for inhibitors of HIV gp120-CD4 binding using an enzyme-linked immunoabsorbent assay.

1993

Binding of the HIV-1 major viral surface glycoprotein, gp120, to the major cell receptor, CD4, is essential for HIV infection of the target cell and syncytium formation. An enzyme-linked immunoassay using solid phase CD4 was used to quantitate the binding of HIV-1 gp120 to CD4, and to assess the activity and mechanism of action of putative inhibitors of that reaction. Monoclonal antibodies to the gp120 binding site on CD4 (e.g., Leu3a) blocked gp120 binding, while monoclonal antibodies to other portions of CD4 (e.g. OKT4) did not. Both aurintricarboxylic acid and sulfonated polysaccharides (e.g., dextran sulfate) blocked CD4-gp120 interactions by binding to the CD4 component. Human polyclon…

medicine.drug_classvirusesEnzyme-Linked Immunosorbent AssayHIV Envelope Protein gp120Monoclonal antibodyAntiviral Agentschemistry.chemical_compoundPolysaccharidesVirologyLectinsAurintricarboxylic acidmedicineGlycoproteinschemistry.chemical_classificationbiologyLigand binding assayvirus diseasesLectinReproducibility of ResultsMolecular biologyRecombinant ProteinsEnzymechemistryMechanism of actionPolyclonal antibodiesCD4 Antigensbiology.proteinHIV-1medicine.symptomAntibodyJournal of virological methods
researchProduct

Hepatitis E seroprevalence and viremia rate in immunocompromised patients: a systematic review and meta‐analysis

2020

Background and aims Hepatitis E is an infectious disease of the liver caused by the hepatitis E virus (HEV). Immunocompromised patients present a particular risk group, as chronification of hepatitis E leading to life-threatening cirrhosis occurs when these patients are infected. Therefore, this study aims to estimate and compare the anti-HEV seroprevalence and the rate of HEV RNA positivity in transplant recipients and patients with human immunodeficiency virus (HIV). Methods This systematic review and meta-analysis involved a literature search (PubMed, Scopus; 1,138 studies) including 120 studies from 1996 to 2019, reporting anti-HEV seroprevalence and/or HEV-RNA positivity. Statistical a…

medicine.medical_specialtyCirrhosisHIV InfectionsViremiamedicine.disease_causeImmunocompromised Host03 medical and health sciences0302 clinical medicineHepatitis E virusSeroepidemiologic StudiesInternal medicineHepatitis E virusmedicineHumansSeroprevalenceHepatitis AntibodiesViremiaHepatologybusiness.industryvirus diseasesmedicine.diseaseHepatitis EHepatitis ETransplantationChronic infectionImmunoglobulin G030220 oncology & carcinogenesisMeta-analysisRNA Viral030211 gastroenterology & hepatologybusinessLiver International
researchProduct

ADAMTS13 and VWF activities guide individualized caplacizumab treatment in patients with aTTP

2020

Abstract Introduction of the nanobody caplacizumab was shown to be effective in the treatment of acquired thrombotic thrombocytopenic purpura (aTTP) in the acute setting. The official recommendations include plasma exchange (PEX), immunosuppression, and the use of caplacizumab for a minimum of 30 days after stopping daily PEX. This study was a retrospective, observational analysis of the use of caplacizumab in 60 patients from 29 medical centers in Germany. Immunosuppressive treatment led to a rapid normalization of ADAMTS13 activities (calculated median, 21 days). In 35 of 60 patients, ADAMTS13 activities started to normalize before day 30 after PEX; in 11 of 60 patients, the treatment was…

medicine.medical_specialtyClinical Trials and Observationsmedicine.medical_treatmentMedizinADAMTS13 Protein030204 cardiovascular system & hematology03 medical and health sciences0302 clinical medicineVon Willebrand factorFibrinolytic AgentsInternal medicinehemic and lymphatic diseasesvon Willebrand FactormedicineHumansIn patientRetrospective StudiesAcquired Thrombotic Thrombocytopenic PurpurabiologyPurpura Thrombotic Thrombocytopenicbusiness.industryImmunosuppressionRetrospective cohort studyHematologySingle-Domain AntibodiesADAMTS13Cardiovascular and Metabolic Diseases030220 oncology & carcinogenesisbiology.proteinBiomarker (medicine)Caplacizumabbusiness
researchProduct

Impact of domestic mould exposure on Aspergillus biomarkers and lung function in patients with chronic obstructive pulmonary disease

2021

International audience; Patients with chronic obstructive pulmonary disease (COPD) are frequently colonised or sensitised by Aspergillus, but clinical significance remains unclear. Furthermore, little is known on the impact of indoor mould exposure during COPD. In this study, we assessed the relationship between domestic mould exposure, Aspergillus biomarkers and COPD severity during acute exacerbation and at stable state. Aspergillus section Fumigati culture in sputum and anti-Aspergillus antibodies detection (IgG and precipitins) were followed up in COPD patients that were prospectively recruited during exacerbation (n = 62), and underwent a visit at stable state after 18 months (n = 33).…

medicine.medical_specialtyExacerbationMESH: Pulmonary Disease Chronic Obstructive010501 environmental sciencesEnvironmentMESH: Forced Expiratory VolumeAspergillosis01 natural sciencesBiochemistryGastroenterologyPulmonary Disease Chronic Obstructive03 medical and health sciences0302 clinical medicineanti-Aspergillus antibodiesForced Expiratory VolumeInternal medicinemedicineAspergillosisHumansCOPDClinical significanceMESH: Lung030212 general & internal medicineMESH: AspergillosisLungLung function0105 earth and related environmental sciencesGeneral Environmental Science[SDV.EE.SANT]Life Sciences [q-bio]/Ecology environment/HealthCOPDAspergillusMESH: Humansbiologybusiness.industryFungimedicine.diseasebiology.organism_classificationrespiratory tract diseasesAspergillusMESH: Aspergillusbiology.proteinMESH: BiomarkersSputummedicine.symptomAntibodybusinessBiomarkers
researchProduct

Caplacizumab prevents refractoriness and mortality in acquired thrombotic thrombocytopenic purpura: integrated analysis

2021

Abstract The efficacy and safety of caplacizumab in individuals with acquired thrombotic thrombocytopenic purpura (aTTP) have been established in the phase 2 TITAN and phase 3 HERCULES trials. Integrated analysis of data from both trials was conducted to increase statistical power for assessing treatment differences in efficacy and safety outcomes. Caplacizumab was associated with a significant reduction in the number of deaths (0 vs 4; P < .05) and a significantly lower incidence of refractory TTP (0 vs 8; P < .05) vs placebo during the treatment period. Consistent with the individual trials, treatment with caplacizumab resulted in a faster time to platelet count response (ha…

medicine.medical_specialtyExacerbationThrombotic thrombocytopenic purpura030204 cardiovascular system & hematologyPlaceboGastroenterology03 medical and health sciences0302 clinical medicineFibrinolytic AgentsRefractoryInternal medicinemedicineHumans610 Medicine & healthAcquired Thrombotic Thrombocytopenic PurpuraPlasma ExchangePurpura Thrombotic Thrombocytopenicbusiness.industryHazard ratioHematologySingle-Domain Antibodiesmedicine.diseaseStimulus ReportTolerability030220 oncology & carcinogenesisCaplacizumabbusinessBlood Advances
researchProduct

Effectiveness of benralizumab in severe eosinophilic asthma: Distinct sub-phenotypes of response identified by cluster analysis

2022

Background: Benralizumab is effective in severe eosinophilic asthma (SEA), but suboptimal responses are observed in some patients. Although several factors have been associated with benralizumab response, no cluster analysis has yet been undertaken to identify different responsiveness sub-phenotypes. Objective: To identify SEA sub-phenotypes with differential responsiveness to benralizumab. Methods: One hundred and five patients diagnosed with SEA who had completed 6 months of benralizumab treatment were included in a hierarchical cluster analysis based on a set of clinical variables that can be easily collected in routine practice (age, age at disease onset, disease length, allergen sensit…

medicine.medical_specialtyExacerbationbiologicals monoclonal antibodies observational studies precision medicine real-lifeprecision medicineImmunologyDiseaseSettore MED/10 - Malattie Dell'Apparato RespiratorioImmunoglobulin EAntibodies Monoclonal Humanizedobservational studiechemistry.chemical_compoundInternal medicinemedicineImmunology and AllergyCluster AnalysisHumansAnti-Asthmatic Agentsreal-lifeobservational studiesmonoclonal antibodieResponse rate (survey)Bronchiectasisbiologybusiness.industrymedicine.diseaseBenralizumabPhenotypeAsthmaEosinophilsPhenotypechemistrybiologicalsbiology.proteinDisease ProgressionBiomarker (medicine)monoclonal antibodiesbusinessbiological
researchProduct

Hepatitis B virus in diabetic patients

1980

The presence of HBV markers was determined in 149 serum samples obtained from diabetic patients and was compared with a normal population. Diabetics have the same incidence of HBsAg but significantly higher anti-HBc antibodies. These differences were seen in the group of diabetics on oral hypoglycemic therapy. These results cannot yet be explained.

medicine.medical_specialtyHBsAgEndocrinology Diabetes and MetabolismHbv markersAntibodies Viralmedicine.disease_causeGastroenterologyHepatitis B AntigensEndocrinologyInternal medicineDiabetes mellitusEpidemiologyDiabetes MellitusInternal MedicinemedicineHumansHepatitis B AntibodiesHepatitis B virusbiologybusiness.industryIncidence (epidemiology)virus diseasesGeneral MedicineSerum samplesmedicine.diseasedigestive system diseasesImmunologybiology.proteinAntibodybusinessActa Diabetologica Latina
researchProduct

HLA antigens and immunoresponsiveness to insulin in insulin-dependent diabetes mellitus.

2008

HLA-A and B antigens were determined in 112 patient with insulin-dependent juvenile onset diabetes mellitus, who could be subdivided into “non” and “high responders” to insulin. The data revealed a trend of an association of these diabetes subgroups with only one of the diabetes-associated antigens HLA-B8 and HLA-BW15 and indicated the existence of at least two different genetic constellations for susceptibility to juvenile diabetes mellitus. One form with a strong immune-response to insulin seemed to be associated with HLA-BW 15 and the other form without humoral immunoreactivity to insulin seemed to be associated with the presence of HLA-B8 and the absence of HLA-B7.

medicine.medical_specialtyHigh respondermedicine.medical_treatmentInsulin AntibodiesImmunologyHuman leukocyte antigenBiochemistryAntigenHLA AntigensDiabetes mellitusInternal medicineHistocompatibility AntigensGeneticsmedicineDiabetes MellitusImmunology and AllergyHumansInsulinbusiness.industryInsulinGeneral Medicinemedicine.diseaseEndocrinologyInsulin dependent diabetesImmunologyJuvenile diabetes mellitusbusinessJuvenile-onset diabetes mellitusTissue antigens
researchProduct

Canakinumab in systemic juvenile idiopathic arthritis: real-world data from a retrospective Italian cohort

2021

Abstract Objective The objective of this study was to use real-world data to evaluate the effectiveness and safety of canakinumab in Italian patients with systemic JIA (sJIA). Methods A retrospective multicentre study of children with sJIA was performed. Clinical features, laboratory parameters and adverse events were collected at baseline, and 6 and 12 months after starting canakinumab. The primary outcome measure of effectiveness was clinically inactive disease (CID) off glucocorticoids (GCs) treatment at 6 months. Results A total of 80 children from 15 Italian centres were analysed. Of the 12 patients who started canakinumab in CID while receiving anakinra, all maintained CID. Of the 68 …

medicine.medical_specialtyMultivariate analysissystemic juvenile idiopathic arthritisArthritisJuvenileAntibodies Monoclonal HumanizedcanakinumabAntibodiessystemic juvenile idiopathic arthritis.Settore MED/38 - Pediatria Generale E SpecialisticaRheumatologyInternal medicineMonoclonalmedicinecanakinumab; clinically inactive disease; systemic juvenile idiopathic arthritis; Antibodies Monoclonal Humanized; Child; Glucocorticoids; Humans; Retrospective Studies; Arthritis Juvenile; Macrophage Activation SyndromeHumanscanakinumab clinically inactive disease systemic juvenile idiopathic arthritis Antibodies Monoclonal Humanized Child Glucocorticoids Humans Retrospective Studies Arthritis Juvenile Macrophage Activation SyndromePharmacology (medical)clinical inactive disease.Adverse effectChildHumanizedGlucocorticoidsRetrospective StudiesUnivariate analysisAnakinrabusiness.industryclinically inactive diseaseArthritisMacrophage Activation Syndromemedicine.diseaseArthritis JuvenileCanakinumabMacrophage activation syndromeCohortSystemic juvenile idiopathic arthritibusinessmedicine.drug
researchProduct